Capricor Therapeutics (CAPR) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month price targets for Capricor Therapeutics' stock. Their CAPR share price forecasts range from $15.00 to $18.00. On average, they anticipate the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 262.6% from the stock's current price.
View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts.

Capricor Therapeutics' stock was trading at $3.86 at the beginning of the year. Since then, CAPR shares have increased by 17.9% and is now trading at $4.55.
View the best growth stocks for 2023 here.

Capricor Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 294,800 shares, an increase of 11.0% from the April 30th total of 265,700 shares. Based on an average daily trading volume, of 72,100 shares, the days-to-cover ratio is presently 4.1 days.
View Capricor Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our CAPR earnings forecast.

Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported ($0.31) EPS for the quarter. The biotechnology company had revenue of $0.96 million for the quarter, compared to analysts' expectations of $0.01 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Capricor Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.56%), Geode Capital Management LLC (0.92%), Dimensional Fund Advisors LP (0.39%), Renaissance Technologies LLC (0.12%), Commonwealth Equity Services LLC (0.12%) and Virtu Financial LLC (0.07%). Insiders that own company stock include David B Musket and Xavier Avat.
View institutional ownership trends.

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CAPR stock can currently be purchased for approximately $4.55.

Capricor Therapeutics (NASDAQ:CAPR) has a market capitalization of $114.98 million and generates $2.55 million in revenue each year. The biotechnology company earns $-29,020,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The official website for the company is www.capricor.com. The biotechnology company can be reached via phone at 310-358-3200, via email at kimberly@argotpartners.com, or via fax at 415-875-7075.